Companies: 10,795·Total market cap: $144.5T
AstraZeneca PLC

AstraZeneca PLC

AZNNYSEHealthcare● Active
$185.95
+$4.15(+2.28%)
Market Cap$288.4B
P/E Ratio—
52W High$212.71
52W Low$137.22
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

AstraZeneca PLC (AZN) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000901832 · AZN · NYSE · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
6-K
Latest Form
2026-06-01
Most Recent
1993
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0000901832 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-02-24
Fiscal Year End
Feb 24, 2026
Accession No.
0001104659-26-019130
Primary Document
azn-20251231x20f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0000901832 · Accession 0001104659-26-019130

Latest Key Filings

6-KQuarterly Report
ADMISSION OF FURTHER SECURITIES TO TRADING
2026-06-01
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
6-KCurrent Report (Foreign Issuer)
ADMISSION OF FURTHER SECURITIES TO TRADING
2026-06-01
View
6-KCurrent Report (Foreign Issuer)
TOTAL VOTING RIGHTS
2026-06-01
View
6-KCurrent Report (Foreign Issuer)
IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER
2026-05-29
View
25-NSE25-NSE
25-NSE
2026-05-28
View
6-KCurrent Report (Foreign Issuer)
US FDA DECISION DATE ON CAMIZESTRANT EXTENDED
2026-05-27
View
6-KCurrent Report (Foreign Issuer)
DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
DIRECTOR/PDMR SHAREHOLDING
2026-05-18
View
6-KCurrent Report (Foreign Issuer)
BAXFENDY APPROVED IN THE US FOR HYPERTENSION
2026-05-18
View
6-KCurrent Report (Foreign Issuer)
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS
2026-05-18
View
6-KCurrent Report (Foreign Issuer)
IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER
2026-05-14
View
6-KCurrent Report (Foreign Issuer)
TOTAL VOTING RIGHTS AND ADMISSION OF SHARES
2026-05-01
View
6-KCurrent Report (Foreign Issuer)
FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER
2026-05-01
View
6-KCurrent Report (Foreign Issuer)
FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER
2026-05-01
View
Showing 1–15 of 993 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000901832  |  Exchange: NYSE · Healthcare

AstraZeneca PLC (NYSE: AZN) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1993. As a Healthcare sector company with CIK 0000901832, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is AstraZeneca PLC's most comprehensive regulatory disclosure. The most recent AstraZeneca PLC 10-K was filed on 2026-02-24 for fiscal year ending 2026. Historical AZN 10-K annual reports are available from 2019 through 2026.

Investors researching AstraZeneca PLC SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
LLY SEC Filings →JNJ SEC Filings →ABBV SEC Filings →RHHBY SEC Filings →MRK SEC Filings →NVS SEC Filings →AMGN SEC Filings →GILD SEC Filings →
→ AZN Financials→ AZN Earnings→ AZN Insider Trades

Frequently Asked Questions

AZN SEC Filings · 8 questions

AstraZeneca PLC (AZN) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. AstraZeneca PLC's CIK is 0000901832.

AZN SEC filingsAstraZeneca PLC SEC documentsfind AZN 10-K